Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.

Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV

International journal of radiation oncology, biology, physics1 Mar 2001Cited by 233 (Europe PMC)

PMID11240234DOI10.1016/s0360-3016(00)01516-9PepBankPUB-11240234

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
After prostate cancer radiation, local failure at 8 years was 23% with immediate goserelin versus 37% with hormones at relapse (p < 0.0001).
In plain wordsAfter prostate cancer radiation, local failure was lower with immediate goserelin than with hormones at relapse.
Peptide
Goserelin
Outcome
DecreaseLocal failure at 8 years
Study
n = 945
Comparator
radiation alone with hormones at relapse
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · long-termAs given in this study (human).
Measurements
Local failure
23%
Arm I
Local failure
37%
Arm II
Source sentences
Summary
With a median follow up of 5.6 years for all patients and 6.0 years for living patients local failure at 8 years was 23% for Arm I and 37% for Arm II (p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In 1987 the RTOG initiated a Phase III trial of long-term adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate.
Summary · context
A total of 977 patients were accrued to the study of which 945 remain analyzable: 477 on the adjuvant hormone arm (Arm I); and 468 on the radiation only arm (Arm II) with hormones initiated at relapse.
Report a problemFND-1124023401
02HumanNon-randomized trialEfficacy outcome
After prostate cancer radiation, distant metastasis occurred in 27% with immediate goserelin versus 37% with hormones at relapse (p < 0.0001).
In plain wordsAfter prostate cancer radiation, distant metastasis was lower with immediate goserelin than with hormones at relapse.
Peptide
Goserelin
Outcome
DecreaseDistant metastasis
Study
n = 945
Comparator
radiation alone with hormones at relapse
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · long-termAs given in this study (human).
Measurements
Distant metastasis
27%
Arm I
Distant metastasis
37%
Arm II
Source sentences
Summary
Distant metastasis was likewise favorably impacted with the immediate use of hormonal manipulation with a distant metastasis rate in Arm I of 27% and 37% in Arm II (p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In 1987 the RTOG initiated a Phase III trial of long-term adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate.
Summary · context
A total of 977 patients were accrued to the study of which 945 remain analyzable: 477 on the adjuvant hormone arm (Arm I); and 468 on the radiation only arm (Arm II) with hormones initiated at relapse.
Report a problemFND-1124023402
03HumanNon-randomized trialEfficacy outcome
After prostate cancer radiation, immediate goserelin improved disease-free survival versus hormones at relapse (p < 0.0001).
In plain wordsAfter prostate cancer radiation, immediate goserelin improved disease-free survival versus hormones at relapse.
Peptide
Goserelin
Outcome
IncreaseDisease-free survival
Study
n = 945
Comparator
radiation alone with hormones at relapse
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · long-termAs given in this study (human).
Source sentences
Summary
Disease-free survival (NED survival) and NED survival with PSA of 1.5 ng/mL (bNED) or less were both statistically significant in favor of the immediate hormone arm (both p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In 1987 the RTOG initiated a Phase III trial of long-term adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate.
Summary · context
A total of 977 patients were accrued to the study of which 945 remain analyzable: 477 on the adjuvant hormone arm (Arm I); and 468 on the radiation only arm (Arm II) with hormones initiated at relapse.
Report a problemFND-1124023403
04HumanNon-randomized trialEfficacy outcome
After prostate cancer radiation, immediate goserelin improved NED survival with PSA at or below 1.5 ng/mL versus hormones at relapse (p < 0.0001).
In plain wordsAfter prostate cancer radiation, immediate goserelin improved biochemical disease-free survival versus hormones at relapse.
Peptide
Goserelin
Outcome
IncreaseBiochemical disease-free survival
Study
n = 945
Comparator
radiation alone with hormones at relapse
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · long-termAs given in this study (human).
Source sentences
Summary
Disease-free survival (NED survival) and NED survival with PSA of 1.5 ng/mL (bNED) or less were both statistically significant in favor of the immediate hormone arm (both p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In 1987 the RTOG initiated a Phase III trial of long-term adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate.
Summary · context
A total of 977 patients were accrued to the study of which 945 remain analyzable: 477 on the adjuvant hormone arm (Arm I); and 468 on the radiation only arm (Arm II) with hormones initiated at relapse.
Report a problemFND-1124023404
05HumanNon-randomized trialEfficacy outcome
After prostate cancer radiation, cause-specific failure was 16% with immediate goserelin versus 21% with hormones at relapse (p = 0.23).
In plain wordsAfter prostate cancer radiation, cause-specific failure did not differ significantly between immediate goserelin and hormones at relapse.
Peptide
Goserelin
Outcome
No significant changeCause-specific failure
Study
n = 945
Comparator
radiation alone with hormones at relapse
Outcome group
Mortality · Cancer
Studied dose
Dose not stated · long-termAs given in this study (human).
Measurements
Cause-specific failure
16%
Arm I
Cause-specific failure
21%
Arm II
Source sentences
Summary
Cause-specific failure was not statistically different with a cause-specific failure of 16% for Arm I and 21% in Arm II (p = 0.23).
2 context sentences(design, population, supporting numbers)
Summary · context
In 1987 the RTOG initiated a Phase III trial of long-term adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate.
Summary · context
A total of 977 patients were accrued to the study of which 945 remain analyzable: 477 on the adjuvant hormone arm (Arm I); and 468 on the radiation only arm (Arm II) with hormones initiated at relapse.
Report a problemFND-1124023405
06HumanNon-randomized trialEfficacy outcome
After prostate cancer radiation, overall survival at 8 years was 49% with immediate goserelin versus 47% with hormones at relapse (p = 0.36).
In plain wordsAfter prostate cancer radiation, overall survival did not differ significantly between immediate goserelin and hormones at relapse.
Peptide
Goserelin
Outcome
No significant changeOverall survival at 8 years
Study
n = 945
Comparator
radiation alone with hormones at relapse
Outcome group
Mortality · Cancer
Studied dose
Dose not stated · long-termAs given in this study (human).
Measurements
Overall survival
49%
Arm I
Overall survival
47%
Arm II
Source sentences
Summary
Overall survival was likewise not statistically different between two arms, with a 49% overall survival at 8 years in Arm I and 47% in Arm II (p = 0.36).
2 context sentences(design, population, supporting numbers)
Summary · context
In 1987 the RTOG initiated a Phase III trial of long-term adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate.
Summary · context
A total of 977 patients were accrued to the study of which 945 remain analyzable: 477 on the adjuvant hormone arm (Arm I); and 468 on the radiation only arm (Arm II) with hormones initiated at relapse.
Report a problemFND-1124023406
07HumanNon-randomized trialEfficacy outcome
In centrally reviewed Gleason 8-10 patients without prostatectomy, immediate goserelin after radiation improved absolute survival versus hormones at relapse (p = 0.036).
In plain wordsIn Gleason 8-10 patients without prostatectomy, immediate goserelin after radiation improved absolute survival versus hormones at relapse.
Peptide
Goserelin
Outcome
IncreaseAbsolute survival in Gleason 8-10 subgroup
Study
n: not reported in source
Comparator
radiation alone with hormones at relapse
Outcome group
Mortality · Cancer
Studied dose
Dose not stated · long-termAs given in this study (human).
Source sentences
Summary
Subset analysis of centrally reviewed Gleason 8-10 patients who did not undergo prostatectomy showed that for patients receiving radiation therapy plus adjuvant hormones there was a statistically significant improvement in both absolute (p = 0.036) and cause-specific survival (p = 0.019).
2 context sentences(design, population, supporting numbers)
Summary · context
In 1987 the RTOG initiated a Phase III trial of long-term adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate.
Summary · context
A total of 977 patients were accrued to the study of which 945 remain analyzable: 477 on the adjuvant hormone arm (Arm I); and 468 on the radiation only arm (Arm II) with hormones initiated at relapse.
Report a problemFND-1124023407
08HumanNon-randomized trialEfficacy outcome
In centrally reviewed Gleason 8-10 patients without prostatectomy, immediate goserelin after radiation improved cause-specific survival versus hormones at relapse (p = 0.019).
In plain wordsIn Gleason 8-10 patients without prostatectomy, immediate goserelin after radiation improved cause-specific survival versus hormones at relapse.
Peptide
Goserelin
Outcome
IncreaseCause-specific survival in Gleason 8-10 subgroup
Study
n: not reported in source
Comparator
radiation alone with hormones at relapse
Outcome group
Mortality · Cancer
Studied dose
Dose not stated · long-termAs given in this study (human).
Source sentences
Summary
Subset analysis of centrally reviewed Gleason 8-10 patients who did not undergo prostatectomy showed that for patients receiving radiation therapy plus adjuvant hormones there was a statistically significant improvement in both absolute (p = 0.036) and cause-specific survival (p = 0.019).
2 context sentences(design, population, supporting numbers)
Summary · context
In 1987 the RTOG initiated a Phase III trial of long-term adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate.
Summary · context
A total of 977 patients were accrued to the study of which 945 remain analyzable: 477 on the adjuvant hormone arm (Arm I); and 468 on the radiation only arm (Arm II) with hormones initiated at relapse.
Report a problemFND-1124023408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.